Peer Review: Don Hayden commits to CEO role at WindMIL; X4 nabs new CMO Lynne Kelley from Histogenics exile
→ Since leaving a 25-year career and the president of global pharmaceuticals title at Bristol-Myers Squibb in 2005, Don Hayden has kept himself busy as a consultant and adviser to biopharma companies, sometimes juggling seven or eight board appointments. But after a few months as interim CEO of WindMIL Therapeutics, he’s ready to “substantially pull back” on all those commitments as he transitions to a full-time role.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
